Titlebook: Diagnostic and Therapeutic Advances in Hematologic Malignancies; Martin S. Tallman,Leo I. Gordon Book 1999 Springer Science+Business Media

一再遛

Therapy of diffuse aggressive lymphomas,n of either B or T lymphocytes but differing in clinical presentation, prognosis, and treatment strategies. In 1997, the estimated number of new cases of NHL was 53,600, with a slight preponderance toward males (M/F ratio: 1.3).. The estimated number of deaths secondary to NHL was 23,800 (44.4%) in

詳細(xì)目錄

CHOKE

冬眠

Prognosis in multiple myeloma,or physicians to be able to discuss natural history with patients and tailor therapeutic modalities according to expected outcome, accurate prognostic systems are needed. Although several factors have been found to be prognostic in myeloma, there is no definitive consensus on which combination of th

準(zhǔn)則

宣傳

Hematopoietic growth factors and acute leukemia, leukemia, and these will be discussed in this chapter. Several areas have been explored extensively, and many data are available from clinical trials. Other areas are of potential interest but have a paucity of clinical information. The past decade has seen major strides in the development and clin

不持續(xù)就爆

Novel treatment approaches for cutaneous T-cell lymphoma,e controversy exists, however, regarding the curability of this indolent disease process with currently described modalities. The lack of convincing survival benefit to patients in randomized trials of aggressive multimodality therapy compared with palliative treatments suggests that long disease-fr

變色龍